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ABSTRACT: INTRODUCTION: Oral Mucosa Melanoma 
(MMO) is a rare malignant neoplasm that accounts for about 
0.5% of all oral tumors. This melanoma is associated with atypical 
proliferation of melanocytes present in the mucosal epithelium. 
The treatment can be performed by surgical resection, with 
chemotherapy and radiotherapy as adjunct treatment. In cases with 
metastatic lymph nodes, adjuvant treatment with immunotherapy 
may be used. CASE REPORT: An 83-year-old male patient 
had as main complaint a dark tumor in the gingiva, hard palate 
and right maxillary sinus, with cervical and mediastinal lymph 
nodes and pulmonary metastases. In 2015, he started treatment 
with DTIC and obtained partial response. After one year, he 
started treatment with Imatinib, obtained partial response and 
then disease progression. In 2016, he started treatment with 
Nivolumab and local radiotherapy with IMRT. He had complete 
local remission and partial systemic remission. Moreover, 
the treatment had as immune-mediated side effects adrenal 
insufficiency, hypothyroidism, diabetes mellitus and vitiligo 
on face and left flank. Our report aims to present a case of oral 
mucosal melanoma in the gingiva, palate and maxillary sinus with 
systemic metastases, treated with Nivolumab and radiotherapy, 
compare it with other reports in the literature and highlight the 
complications of immunotherapy. 
Keywords:  Melanoma; Immunotherapy; Nivolumab; 
Radiotherapy.
RESUMO: INTRODUÇÃO: O Melanoma de Mucosa Oral 
(MMO) é uma neoplasia maligna rara, corresponde a cerca de 
0,5% de todos os tumores orais. Este melanoma ocorre devido 
a proliferação atípica de melanócitos presentes no epitélio das 
mucosas do organismo. O tratamento é realizado por ressecção 
cirúrgica, quimioterapia e radioterapia como tratamento adjuvante. 
Nos casos com linfonodos metastáticos pode-se usar o tratamento 
adjuvante com imunoterapia. RELATO DE CASO: Paciente 83 
anos, sexo masculino, teve como queixa principal tumoração de 
cor escura em gengiva, palato duro e seio maxilar direito, com 
linfonodos metastáticos cervicais e mediastinais e metástases 
pulmonares. Em 2015, iniciou tratamento com DTIC com resposta 
parcial e após um ano, iniciou a terapêutica com Imatinibe com 
resposta parcial e depois progressão da doença. Em 2016, iniciou 
tratamento com Nivolumabe e radioterapia local com IMRT. 
Apresentou remissão completa local e parcial sistêmica. Também 
apresentou como efeitos colaterais imunomediados insuficiência 
suprarrenal, hipotireoidismo, diabetes melitus e vitiligo em face e 
flanco esquerdo. Nosso relato tem como objetivo apresentar um 
caso de melanoma de mucosa oral na região da gengiva, palato e 
seio maxilar com metástases sistêmicas, tratado com Nivolumabe 
e radioterapia, e com isso comparar com outros relatos existentes 
na literatura e ressaltar as complicações da imunoterapia.
Palavras-chave: Melanoma; Imunoterapia; Nivolumabe; 
Radioterapia.
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INTRODUCTION
Oral Mucosal Melanoma (OMM) is a rare malignant neoplasm that is distinct from other 
melanomas that appear on the skin. It represents 0.2% to 
8% of all melanomas and 0.5% of all oral tumors1. As 
melanocytes are abundant in the skin, melanoma can be 
found in small numbers in the mucosa of the digestive, 
respiratory and genitourinary systems, as well as in the 
eye. Melanoma occurs due to the atypical proliferation 
of melanocytes in the mucosa of these organs and is 
characterized by the aggressive vertical growth of these 
cells.
Of the 87,110 melanoma cases diagnosed in the 
United States in 2017/2018, less than 2% are in the mucosa: 
31% to 55% are in the head and neck, 17% to 24% are in the 
anorectal area and 18% to 40% are in the vulva and vagina. 
While cutaneous melanoma is slightly more common in 
men than in women, the incidence of mucosal melanoma 
is 87% higher in women than in men2,3,4.
The epidemiology of mucosal melanoma is different 
from cutaneous melanoma. Melanomas of the oral cavity 
represent almost 30% of the mucosal melanomas of the 
head and neck and usually affect the palate and buccal 
gingiva. Mucosal melanomas are usually diagnosed at 
advanced stages and have poor prognosis and survival. The 
5-year survival rate for head and neck mucosal melanoma 
ranges from 17% to 35%. The prognosis, however, seems 
to vary according to the location: lesions in the nasal cavity 
have a more favorable prognosis than those of the sinuses5,6.
An analysis of 93 patients with mucosal melanoma 
showed c-KIT mutations in 18.2% of melanomas, BRAF 
mutations in 12% and NRAS mutations in 10%. NFI 
appears in 20% of melanomas of the anorectal mucosa, 
while BRAF appears in 52% of cutaneous melanomas7 .
The main treatment for localized oral melanoma 
is wide surgical resection with radiotherapy as adjuvant 
treatment (5)(8). After surgical resection, the recommendation 
of adjuvant treatment is based on a phase III study conducted 
in China. In this study, 204 patients that underwent complete 
resection were randomized to receive alpha interferon or 
chemotherapy with cisplatin and temozolomide for 6 
cycles. The study had a median follow-up of 23.7 months 
and disease-free survival was 16.80 months for patients 
on alpha interferon versus 9.57 months for patients on 
chemotherapy. For metastatic melanoma, treatment with 
targeted BRAF inhibitors (dabrafenib and trametinib), 
anti-PD-1 antibodies (nivolumab and pembrolizimab) and 
anti-CTLA-4 (ipilumumab) is currently recommended 
as adjuvant and palliative treatment according to the 
occurrence of mutations and other factors9,10.
CASE REPORT
The patient is an 83-year-old Brazilian white 
male, retired military police officer, currently undergoing 
treatment at the Oncology and Chemotherapy Simões 
Institute (ISOQ). In 2015, the main complaint of the patient 
was a dark tumor on the hard palate, gingiva and right 
side of the maxillary sinus, in addition to bilateral level II 
metastatic cervical lymph nodes. He also had metastatic 
mediastinal lymph nodes and lung metastases shown on 
imaging tests and PET-CT scans. A lung biopsy confirmed 
a metastatic melanoma of the lung. His personal history 
includes diabetes treated with metformin, prostate cancer 
confirmed by biopsy, with Gleason score of 8 and 6, treated 
with agonist LHRH since 2013 and SAH and diabetes with 
stable PSA. Patient denies family history of melanoma.
In March 2015, the patient was diagnosed with 
Mucosal Melanoma of the palate and gingiva with invasion 
of the right maxillary sinus and started treatment by the SUS 
in another institution. The physical examination showed 
a dark ulcerated exophytic tumor in the hard palate and 
gingiva, invading the right maxillary sinus, and bilateral 
level II metastatic cervical lymphadenopathy. An open lung 
biopsy showed metastasis of the melanoma (stage IV b). 
The patient started treatment with DTIC (Dacarbazine) for 
six cycles and obtained a partial response. At the beginning 
of 2016, he started treatment at the ISOQ with Imatinib 
(Glivec) for cKIT-Positive, BRAF-negative and normal 
LDH for 6 cycles and obtained partial response.
After local and systemic progression of the 
disease, in August 2016, the patient started treatment with 
Nivolumab 200 mg IV every fortnight and, after 4 cycles, 
he started local radiotherapy with IMRT. He obtained 
complete locoregional response in the following months 
and an important systemic response, confirmed by imaging 
tests and PET-CT. Brain MRI was normal.
After 6 months, there were adverse immunological 
effects: adrenal insufficiency with a baseline cortisol level 
of 0.14 (nv 6.70 to 22.60), which was managed with oral 
Prednisone and maintained with 5 mg VO 12/12 h, and 
hypothyroidism with 7.17 TSH (nv - 4.6), treated with 
Puran T4 50 ucg/day. He also had vitiligo in the face and 
left flank. In 2018, his diabetes got worse and he needed 
insulin treatment, which is maintained until today. The 
patient remained in complete response for more than 3 years 
without progression of the disease, which was confirmed 
by a PET-CT and brain MRI.
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Source: the author. 
Figure 1. Patient on the day of admission in August 2016 - 
Oroscopy - Melanoma in the gingiva and hard palate with 
invasion of the maxillary sinus before treatment with Nivolumab 
and radiotherapy
Source: The author
Figure 2. Patient in December 2016 with complete response after 
starting treatment with Nivolumab and radiotherapy
Source: The author
Figure 3. Patient in August 2019 - Full response maintained
Source: The author
Figure 4. Patient in April 2017 - Vitiligo in the face.
Source: The author
Figure 5. Patient in March 2018 - Onset of vitiligo in the flank
Source: The author
Figure 6. PET-CT exams on the admission date in 2016, two 
years after starting treatment with Nivolumab and radiotherapy 
(2018), and in August 2019, with response to treatment, from left 
to right, respectively
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DISCUSSION
Primary oral mucosal melanomas (POMM) are 
neoplasms that originate from mutations of melanocytes, 
which are the cells responsible for the production of 
melanin. They were first described by Weber in 1859 and 
account for 0.2% to 8% of all melanomas and about 0.5% 
of all malignant neoplasms of the oral cavity6,9. They have 
a higher incidence in China and usually affect individuals 
in their 5th to 7th decades of life6,7. The literature indicates 
a higher incidence among males, as shown in the case 
reported here and in a study by Sortino-Rachou et al.11, 
which found a prevalence of 54.54% of males in a sample 
containing 319 individuals. It is believed that the higher 
incidence among men is due to smoking habits and alcohol 
consumption9. However, some studies indicate a higher 
incidence among females, as the study by Umeda et al.12, 
which found a prevalence of 66.66% of females. In general, 
its etiology is not specific, and it is currently believed that 
POMM is associated with intracellular and genetic factors.
The most affected sites are the palate and the 
gingiva9. According to Singh et al.13, in a total of 1277 
patients evaluated in 16 articles included in the meta-
analysis, 34.29% had a tumor on the palate, while 8.88% 
had a neoplasm on the gingiva. Other sites where these 
lesions can appear include the oral mucosa, tongue, 
mandible, lips, pharynx and larynx, which are rarer 
presentations of oral melanoma6,9. In this case report, the 
patient had a tumor in the gingiva and hard palate with 
invasion of the right maxillary sinus, corroborating the 
epidemiology reported in the literature.
Melanoma has an asymptomatic onset, difficult 
visualization, and few clinical signs1,9,14. The initial 
symptom of melanoma is usually a dark macule and 
edema that progresses to an ulcer on the hard palate7,15. 
The literature suggests that lesions are usually brownish 
or black macules, with asymmetric and irregular borders (6)
(9). As the disease progresses, symptoms may include pain, 
tumor, ulcers and bleeding. Metastasis is also common, 
which partially explains the high mortality rates and the 
frequent late diagnosis6,7,14,16.
 In this report, the presentation was the most common 
in the literature: a black and ulcerated tumor, bilateral 
cervical metastatic lymphadenopathy, and metastasis in the 
mediastinal lymph nodes and lungs. López et al.17 found 
that 25% of the patients with oral cavity melanomas present 
with lymph node metastases, while Umeda et al.18 reported 
that distant metastasis is also common. In an analysis of 35 
patients conducted by Tanaka et al.19, regional and distant 
metastases occurred in 18 and 23 cases, respectively, and 
the most distant metastases involved the lungs, which is in 
agreement with the data found in this report. The results of 
this study also reinforce the high mortality rates due to late 
diagnosis, as metastatic disease was already present at the 
time of the diagnosis of melanoma.
Histologically, the tumor has a wide variety of 
elements (probably because the disease is usually diagnosed 
late). An analysis of 32 cases of primary oral melanoma 
by Smith et al.1 showed that cell types differ significantly 
among patients and that most cases displayed a polymorphic 
cell population, with a greater predominance of epithelioid 
cells and “spindle cells” (both present in 50% of cases).
The pathogenesis of oral melanoma is complex 
and involves the interaction between several cytogenetic 
factors, including the cell cycle, dysregulation of c-KIT 
signaling, apoptosis, and cell-cell interaction6,7,9,20. There 
is substantial evidence that hyperactive receptor tyrosine 
kinase (RTK) signaling mediates the development and 
progression of melanoma. In addition, the c-KIT gene 
regulates the activity of the microphthalmia-associated 
transcription factor, which is a leucine transcription 
factor that is essential for melanogenesis and melanocyte 
function6. Therefore, it is believed that c-KIT alterations 
produce oncogenic factors that lead to the development of 
oral melanoma. Mutations in the NRAS or BRAF genes 
can be found less frequently in these melanomas, as they 
are more common in cutaneous melanomas7. In the case 
presented, the patient presented with only a c-KIT mutation.
In general, the disease prognosis is poor, worse 
than skin lesions. The size of the tumor and the presence 
of metastasis are the main factors that determine the 
prognosis6,7,21. A study conducted by Lopez-Graniel et al.22 
evaluated 15 patients diagnosed with primary melanoma 
of the oral cavity during a 15-year period and found that 
the 5-year survival rate was 6.6%, and the only patients 
who survived free of disease for more than 5 years were 
those who had a small tumor and no evidence of lymph 
node metastasis.
The treatment of local oral mucosal melanoma 
is surgical resection when possible and eventual 
reconstruction using local flaps. Metastatic lymph nodes 
in the neck are treated with radical or selective cervical 
lymphadenectomy12. After surgical resection, the use of 
adjuvant chemotherapy with cisplatin and temozolomide 
for 6 cycles should be considered.
Radiotherapy after surgery improves local control, 
but there is no evidence it improves overall survival23. In 
a retrospective study with 160 patients with nonmetastatic 
head and neck mucosal melanoma treated from 1980 
through 2007, Benlyazid et al.24 evaluated the pattern of 
recurrence among individuals treated only with surgery and 
individuals who received radiotherapy after surgery. It was 
found that the survival rate was the same in both groups, but 
the local recurrence rate was lower in those who received 
radiotherapy. In addition, treatment with radiotherapy in the 
primary lesion of the oral mucosa and other sites can lead 
to an abscopal effect. This effect is not very common in the 
clinical area, but it can present itself subtly in radiotherapy 
treatments and induce distant immune response25.
Systemic treatment with monoclonal anti-
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PD-1 antibodies, immune checkpoint inhibitors and 
anti-programmed death antibodies (nivolumab and 
pembrolizumab) is indicated as adjuvant treatment 
in patients with metastatic lymph nodes and distant 
metastasis6,15,20, which justifies the treatment with 
immunotherapy in this case report. Currently, the literature 
suggests the associated use of monoclonal antibodies such as 
anti-PD-1 and anti-CTLA-4 (ipilimumab) as an alternative 
treatment for advanced cases20. Monoclonal antibodies 
block inhibitory T-cells (CTLA-4) and programmed death 1 
(PD-1). PD-1 is part of the CD28 family, and the interaction 
with its two ligands (PD-L1 and PD-L2) occurs mainly 
in peripheral tissues, including the tumor environment, 
leading to apoptosis and downregulation of the effector 
function of T cells26. CTLA-4, on the other hand, is a 
receptor expressed in T cells that, when interacting with 
its ligands, inhibits the activity of these cells27.
These treatments, however, can have immune-
related complications such as adrenal insufficiency, 
hypothyroidism, hepatotoxicity, vitiligo, diabetes, 
dermatitis, pneumonitis, pituitary metastasis, among 
others. Among these effects, the patient in this report had 
adrenal insufficiency, hypothyroidism, vitiligo and diabetes. 
Adrenal insufficiency occurred in the reports by Sakagushi 
et al.20 and Kokkali et al.28, in which hydrocorticoids 
were used as treatment. There was also hypothyroidism 
in the case reported by Kokkali et al., in which hormone 
replacement therapy was used. The reports by Liu et al.29, 
Fukuchi et al.30, Alzenald et al.31 and Maekawa, et al.32 
identified vitiligo and diabetes.
Due to its low incidence, results of studies related 
to the immune treatment of mucosal melanomas are 
scarce. However, it is currently known that the response to 
immunotherapy in mucosal melanomas is lower than in skin 
melanomas23. A systematic analysis by D’Angelo et al.33 
evaluated 86 patients with metastatic mucosal melanoma 
treated only with nivolumab and another 35 patients treated 
with nivolumab and ipilimumab. The study confirmed 
that immunotherapy benefits patients in the treatment of 
the disease, but the objective response rate was relatively 
low (and lower than the rates obtained in studies involving 
cutaneous melanoma in general): in monotherapy with 
nivolumab the response rate was 23.3% and in combination 
therapy, 37.1%. A study by Shoushtari et al.34 analyzed 35 
patients with mucosal melanoma treated with anti-PD-1 
monotherapy (nivolumab or pembrolizumab) and found 
that only 23% of the patients had an objective response. 
These results not only demonstrate that the immunotherapy 
response in mucosal melanoma is relatively low, but also 
indicate greater effectiveness of combined immunotherapy, 
especially the association between nivolumab and 
ipilimumab, which has a higher response rate than mono-
immunotherapy23.
According to Tumeh et al.35, the presence of 
tumor-infiltrating lymphocytes (TILs) can be an important 
predictor of the response to anti-PD-1 agents. However, 
there are few studies that address the prevalence of these 
lymphocytes in melanomas. Still, according to Song et 
al.36, the presence of tumor-infiltrating lymphocytes is 
apparently associated with a lower risk of metastasis in 
mucosal melanomas of the oral cavity.
The real reason why the response is lower in 
mucosal melanomas is not yet known, but it has been 
hypothesized that response to immunotherapy correlates 
with the number of mutations in a tumor and its antigen 
load. As mucosal melanoma is not induced by sun damage, 
as is the case of cutaneous melanoma, the first is associated 
with a lower mutational burden and, therefore, poorer 
response to immunotherapy23.
The literature suggests that the treatment of advanced 
melanoma with Nivolumab may bring certain benefits, such 
as an increased survival rate37, but highlights its side effects 
and the need to intervene with corticosteroids to reduce 
immune-mediated damage20. As demonstrated in this report, 
treatment with Nivolumab induced a significant response 
to metastatic disease in the patient and had a significant 
role in the treatment of melanoma, but the onset of side 
effects in the patient led to the use of corticosteroids (oral 
prednisone) to treat adrenal insufficiency, levothyroxine 
to treat hypothyroidism and insulin to treat diabetes (in 
addition to the presence of vitiligo in the face and left flank).
 
CONCLUSION
Oral melanoma of the head and neck is a rare 
tumor, with late diagnosis, more aggressive than cutaneous 
melanoma, and with a worse prognosis. Current treatment 
with immunotherapy has shown good results and increased 
survival even in patients with metastatic disease. In the case 
presented, the patient had complete locoregional response 
in the mouth, maxillary sinus, and lymph nodes for more 
than 3 years, with no evidence of disease progression in 
the lungs and mediastinal lymph nodes (confirmed by 
PET-CT). However, there were some immune-mediated 
complications, which were treated appropriately.
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